0 results for 'Bristol-Myers Squibb Pharmaceuticals'
2nd Circuit Upholds Dismissal of Securities Suit Targeting Bristol-Myers Squibb Over Failed Trial
The panel upheld a lower court's dismissal of a proposed securities class action, which claimed that Bristol-Myers Squibb made material misstatements or omissions around a clinical trial to determine the drug's efficacy for treating certain kinds of lung cancers.Ex-Amgen In-House Leader Joins Veracyte as General Counsel
Annie McGuire worked her way up the legal department ladder at Amgen and, later, helped lead a biopharma startup through a $13 billion acquisition.Bristol-Myers Squibb, Celgene Face Antitrust Suit Over Cancer Drugs
This suit was surfaced by Law.com Radar. Read the document here.Sambrano v. United Airlines, Inc.
As the coronavirus pandemic continues, courts are grappling with pandemic-related issues such as whether COVID-19 vaccine mandates must provide for religious exemptions. We will survey some recent court rulings.View more book results for the query "Bristol-Myers Squibb Pharmaceuticals"
Patent Infringement Suit Against Bristol-Myers, Celgene Targets Multiple Sclerosis Treatment
This suit was surfaced by Law.com Radar. Read the document here.A Quiet US Supreme Court Term Ahead for IP—With One Potential Explosion
The court is seeking the solicitor general's views on a case that could reset the court's much-maligned patent eligibility law. Beyond that, a fair use case over Andy Warhol artwork and patent dispute over biologic drugs offer a chance of fireworks.A Quiet US Supreme Court Term Ahead for IP—With One Potential Explosion
Stanford law professor Mark Lemley said he believes the justices would much prefer not to wade back into patent eligibility. But, he said, American Axle and Manufacturing v. Neapco "has an interesting spin because it will look to the justices like real technology, not the weak patents they have encountered before."Relator, who brought suit on behalf of the government against a company for overcharging for office equipment, failed to show how the lower court erred in dismissing the case.
AG Discloses Connecticut's Share: $1.3M From $75M Multistate Settlement With Bristol-Myers Squibb
Connecticut's Medicaid program will get a seven-figure infusion.Corporate Transparency Act Resource Kit
Brought to you by Wolters Kluwer
Download Now
Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now